The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|June 19, 2020
CPhI North America Canceled
Author(s)Pharmaceutical Technology Editors
The decision was made in order to give exhibitors enough time to adjust their plans in the wake of the continuing spread of COVID-19.
Advertisement
CPhI North America, organized by Informa Markets, announced on June 19, 2020 that the CPhI event, which was originally scheduled for Sept.9–11, 2020 at the Pennsylvania Convention Center in Philadelphia, PA, will be canceled. The decision was made in order to give exhibitors enough time to adjust their plans in the wake of the continuing spread of COVID-19, an Informa press release said.
“This conclusion was not one that was reached easily, but with the health and safety of our community in mind, we have made the proactive decision to act now,” the press release said. “We understand how important CPhI North America is to the industry and how much effort goes into preparing for it and so, in this difficult time, we would like to thank our community for its understanding and support.”
CPhI also announced it will host a series of webinars in place of the in-person show.
“While our live event has been cancelled, learning never stops,” the press release said. “We have a series of webinars on trending topics coming up soon, and we’ll keep you posted on the details as we finalize them.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement